We use cookies to enhance your browsing experience and analyze site traffic. By continuing to use this site, you agree to our cookie policy. Privacy Policy
As candidate pools grow, the real question becomes which candidates are worth advancing. Click.mAb. now offers candidate list management and five-dimensional developability risk analysis, helping R&D teams centralize candidate sequences and assess potential risks across aggregation, chemical modification, humanness, polyreactivity, and viscosity to support candidate selection and optimization decisions.
In antibody R&D, teams often need to compare and screen multiple candidate molecules. Each candidate differs in sequence, structure, and developability risk. Identifying potential issues early and determining which candidates are more suitable for further advancement is a critical step in candidate selection.
As the number of candidates grows, so does the complexity of evaluation. Promising candidates may be scattered across different conversations, computational tasks, and files. Even after they are collected, the question of which candidate is worth advancing usually cannot be answered by a single metric. For example:
· Does it show a potential tendency toward aggregation?
· Does the sequence contain potential chemical liability sites?
· Does it show favorable humanness characteristics?
· Does it show a tendency toward non-specific binding?
· Is there a potential viscosity-related risk at high concentration?
To address this, Click.mAb. brings candidate management and developability analysis together: first consolidating candidates of interest, then continuously reviewing sequence, structure, and multi-dimensional risk information for the same candidate. This turns scattered candidate sequences into a persistent view that supports ongoing analysis, comparison, and discussion.
In Click.mAb., researchers can add existing antibody sequences to a Candidate List and review sequence information, structural information, and developability analysis results. Candidates that are screened and identified as worth further attention can be retained for subsequent analysis, comparison, and discussion.
Illustration of the information shown in the candidate list
Centralizing candidates only solves the management problem. Actual candidate comparison still requires a clearer view of each candidate's important characteristics and potential risks. To support this step, Click.mAb. adds five-dimensional developability analysis based on the factors most commonly considered during antibody development.
Illustration of the five-dimensional developability analysis framework
Step 1 | Add a Candidate Antibody Sequence
Researchers can use the AI assistant "XiaoKe" to add existing candidate antibody sequences to the Candidate List.
Step 2 | Structure Prediction & Developability Analysis
The platform generates a 3D structure from the candidate sequence and performs developability analysis across five dimensions: aggregation, chemical modification, humanness, polyreactivity, and viscosity.
Step 3 | Review the Integrated Analysis Results
Once the analysis is complete, you can view the following in the candidate details:
· Overall risk: five-dimensional assessment results and an AI-generated risk summary
· Sequence analysis: CDRs, sequence numbering, liability sites, and physicochemical properties
· Structure analysis: 3D structure, CDR distribution, and liability-site locations
If you already have a few antibody sequences worth closer evaluation, add them to the Candidate List and let XiaoKe complete structure prediction and developability risk assessment. You can then compare how different candidates perform across the five dimensions of aggregation, chemical modification, humanness, polyreactivity, and viscosity.
Clickmab is dedicated to empowering antibody discovery through generative AI and welcomes partners across the ecosystem.